Analysts view Basilea's new derazantinib data

Swiss biopharma firm Basilea (SIX: BSLN) has recently reported positive interim results from the derazantinib Phase II registration trial in intrahepatic cholangiocarcinoma (iCCA, bile duct cancer), which were released earlier than expected.

The promising efficacy shown highlights the potential for the product in FGFR-driven solid tumors, an unmet need. Full data are expected to be available once the study has completed (mid-2020), commented Edison Investment Research analyst Dr Susie Jana.

Basilea in-licensed derazantinib from ArQule (Nasdaq: ARQL) in April 2018. The asset is a complementary addition to its oncology portfolio and the company now has three diversified, early/mid-stage clinical assets targeting cancer resistance in its portfolio.